Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $EWTX vs $INDV | Chartloom

Compare

$EWTX vs $INDV

Edgewise Therapeutics Inc · Indivior Pharmaceuticals, Inc

EWTX

Edgewise Therapeutics Inc

INDV

Indivior Pharmaceuticals, Inc

Compare $EWTX vs $INDV

Comparing Edgewise Therapeutics Inc and Indivior Pharmaceuticals, Inc

EWTXEdgewise Therapeutics Inc

INDVIndivior Pharmaceuticals, Inc

EWTXEdgewise Therapeutics Inc

Market cap

$3.90B

P/E (TTM)

—

Forward P/E (NTM)

19.86x

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

52.8%

52W performance

140.1%

FCF yield

-4.1%

INDVIndivior Pharmaceuticals, Inc

Market cap

$4.29B

P/E (TTM)

12.37x

Forward P/E (NTM)

7.50x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

13.6%

YTD performance

-0.9%

52W performance

48.9%

FCF yield

-2.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EWTX

INDV

Detailed metrics comparison

EWTX

Edgewise Therapeutics Inc

INDV

Indivior Pharmaceuticals, Inc

Market Cap

EWTX$3.90B

INDV$4.29B

Enterprise Value

EWTX$3.83B

INDV$4.55B

Price

EWTX$36.28

INDV$35.42

P/E Ratio

EWTXN/A

INDV12.37x

P/S Ratio

EWTX0.00x

INDV3.22x

EV/Sales

EWTX0.00x

INDV3.42x

EV/EBITDA

EWTX0.00x

INDV10.26x

P/B Ratio

EWTX9.47x

INDV422.91x

P/FCF Ratio

EWTXN/A

INDVN/A

EV/FCF

EWTX-24.12x

INDV-41.75x

PEG Ratio

EWTXN/A

INDV0.41x

Forward P/E (NTM)

EWTX19.86x

INDV7.50x

Forward P/S (NTM)

EWTXN/A

INDV3.13x

Revenue (TTM)

EWTX$0

INDV$1.33B

Revenue Growth (YoY)

EWTXN/A

INDV13.6%

Forward Rev Growth

EWTX0.0%

INDV5.4%

Gross Margin (TTM)

EWTX0.0%

INDV82.0%

Operating Margin (TTM)

EWTX0.0%

INDV30.3%

EBITDA Margin (TTM)

EWTX0.0%

INDV33.1%

Net Margin (TTM)

EWTX0.0%

INDV26.7%

FCF Margin (TTM)

EWTXN/A

INDV-8.2%

Net Income (TTM)

EWTX$-197M

INDV$355M

FCF (TTM)

EWTX$-159M

INDV$-109M

EPS (TTM)

EWTX-$1.83

INDV$2.86

ROE (TTM)

EWTX-3901.0%

INDV159.1%

ROA (TTM)

EWTX-3696.0%

INDV28.1%

ROIC (TTM)

EWTX-3901.0%

INDV29.4%

Cash

EWTX$72M

INDV$222M

Debt

EWTX$0

INDV$487M

Net Cash/Debt

EWTX$72M

INDV$-265M

Current Ratio (TTM)

EWTX16.24x

INDV0.84x

Quick Ratio (TTM)

EWTX16.01x

INDV0.65x

Debt/Equity (TTM)

EWTX0.00x

INDV27.90x

Debt/Assets (TTM)

EWTX0.0%

INDV0.0%

Interest Coverage (TTM)

EWTXN/A

INDVN/A

Net Debt/EBITDA (TTM)

EWTX0.00x

INDV0.00x

Beta

EWTX0.37

INDV0.49

52W Performance

EWTX140.1%

INDV48.9%

YTD Performance

EWTX52.8%

INDV-0.9%

% from 52W High

EWTX-25.2%

INDV-17.3%

% from 52W Low

EWTX154.6%

INDV50.4%

Asset Turnover (TTM)

EWTX0.00x

INDV1.06x

FCF Yield (TTM)

EWTX-4.1%

INDV-2.5%

Earnings Yield (TTM)

EWTX-5.1%

INDV8.3%

Dividend Yield (TTM)

EWTXN/A

INDVN/A

Rule of 40

EWTX0.0

INDV5.4

EV/GP/RG

EWTXN/A

INDV1.40

Ticker research

View EWTX research View INDV research

Metric	EWTX Edgewise Therapeutics Inc	INDV Indivior Pharmaceuticals, Inc
Market & Valuation
Market Cap	$3.90B	$4.29B
Enterprise Value	$3.83B	$4.55B
Price	$36.28	$35.42
P/E Ratio	N/A	12.37x
P/S Ratio	0.00x	3.22x
EV/Sales	0.00x	3.42x
EV/EBITDA	0.00x	10.26x
P/B Ratio	9.47x	422.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.12x	-41.75x
PEG Ratio	N/A	0.41x
Forward P/E (NTM)	19.86x	7.50x
Forward P/S (NTM)	N/A	3.13x
Revenue & Growth
Revenue (TTM)	$0	$1.33B
Revenue Growth (YoY)	N/A	13.6%
Forward Rev Growth	0.0%	5.4%
Profitability
Gross Margin (TTM)	0.0%	82.0%
Operating Margin (TTM)	0.0%	30.3%
EBITDA Margin (TTM)	0.0%	33.1%
Net Margin (TTM)	0.0%	26.7%
FCF Margin (TTM)	N/A	-8.2%
Net Income (TTM)	$-197M	$355M
FCF (TTM)	$-159M	$-109M
EPS (TTM)	-$1.83	$2.86
ROE (TTM)	-3901.0%	159.1%
ROA (TTM)	-3696.0%	28.1%
ROIC (TTM)	-3901.0%	29.4%
Financial Health
Cash	$72M	$222M
Debt	$0	$487M
Net Cash/Debt	$72M	$-265M
Current Ratio (TTM)	16.24x	0.84x
Quick Ratio (TTM)	16.01x	0.65x
Debt/Equity (TTM)	0.00x	27.90x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.37	0.49
52W Performance	140.1%	48.9%
YTD Performance	52.8%	-0.9%
% from 52W High	-25.2%	-17.3%
% from 52W Low	154.6%	50.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.06x
FCF Yield (TTM)	-4.1%	-2.5%
Earnings Yield (TTM)	-5.1%	8.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	5.4
EV/GP/RG	N/A	1.40
Ticker research	View EWTX research	View INDV research

Valuation

P/E Ratio

INDV

12.37x

P/S Ratio

EWTX

0.00x

INDV

3.22x

EV/FCF

INDV

-41.75x

EWTX

-24.12x

Growth & revenue

Revenue Growth TTM

INDV

13.6%

Forward Revenue Growth

INDV

5.4%

EWTX

0.0%

Profitability & performance

Gross Margin

INDV

82.0%

EWTX

0.0%

ROE

INDV

159.1%

EWTX

-3901.0%

FCF Yield %

INDV

-2.5%

EWTX

-4.1%

52-Week Performance

EWTX

140.1%

INDV

48.9%

Detailed metrics comparison

EWTX

Edgewise Therapeutics Inc

INDV

Indivior Pharmaceuticals, Inc

Market Cap

EWTX$3.90B

INDV$4.29B

Enterprise Value

EWTX$3.83B

INDV$4.55B

Price

EWTX$36.28

INDV$35.42

P/E Ratio

EWTXN/A

INDV12.37x

P/S Ratio

EWTX0.00x

INDV3.22x

EV/Sales

EWTX0.00x

INDV3.42x

EV/EBITDA

EWTX0.00x

INDV10.26x

P/B Ratio

EWTX9.47x

INDV422.91x

P/FCF Ratio

EWTXN/A

INDVN/A

EV/FCF

EWTX-24.12x

INDV-41.75x

PEG Ratio

EWTXN/A

INDV0.41x

Forward P/E (NTM)

EWTX19.86x

INDV7.50x

Forward P/S (NTM)

EWTXN/A

INDV3.13x

Revenue (TTM)

EWTX$0

INDV$1.33B

Revenue Growth (YoY)

EWTXN/A

INDV13.6%

Forward Rev Growth

EWTX0.0%

INDV5.4%

Gross Margin (TTM)

EWTX0.0%

INDV82.0%

Operating Margin (TTM)

EWTX0.0%

INDV30.3%

EBITDA Margin (TTM)

EWTX0.0%

INDV33.1%

Net Margin (TTM)

EWTX0.0%

INDV26.7%

FCF Margin (TTM)

EWTXN/A

INDV-8.2%

Net Income (TTM)

EWTX$-197M

INDV$355M

FCF (TTM)

EWTX$-159M

INDV$-109M

EPS (TTM)

EWTX-$1.83

INDV$2.86

ROE (TTM)

EWTX-3901.0%

INDV159.1%

ROA (TTM)

EWTX-3696.0%

INDV28.1%

ROIC (TTM)

EWTX-3901.0%

INDV29.4%

Cash

EWTX$72M

INDV$222M

Debt

EWTX$0

INDV$487M

Net Cash/Debt

EWTX$72M

INDV$-265M

Current Ratio (TTM)

EWTX16.24x

INDV0.84x

Quick Ratio (TTM)

EWTX16.01x

INDV0.65x

Debt/Equity (TTM)

EWTX0.00x

INDV27.90x

Debt/Assets (TTM)

EWTX0.0%

INDV0.0%

Interest Coverage (TTM)

EWTXN/A

INDVN/A

Net Debt/EBITDA (TTM)

EWTX0.00x

INDV0.00x

Beta

EWTX0.37

INDV0.49

52W Performance

EWTX140.1%

INDV48.9%

YTD Performance

EWTX52.8%

INDV-0.9%

% from 52W High

EWTX-25.2%

INDV-17.3%

% from 52W Low

EWTX154.6%

INDV50.4%

Asset Turnover (TTM)

EWTX0.00x

INDV1.06x

FCF Yield (TTM)

EWTX-4.1%

INDV-2.5%

Earnings Yield (TTM)

EWTX-5.1%

INDV8.3%

Dividend Yield (TTM)

EWTXN/A

INDVN/A

Rule of 40

EWTX0.0

INDV5.4

EV/GP/RG

EWTXN/A

INDV1.40

Ticker research

View EWTX research View INDV research

Metric	EWTX Edgewise Therapeutics Inc	INDV Indivior Pharmaceuticals, Inc
Market & Valuation
Market Cap	$3.90B	$4.29B
Enterprise Value	$3.83B	$4.55B
Price	$36.28	$35.42
P/E Ratio	N/A	12.37x
P/S Ratio	0.00x	3.22x
EV/Sales	0.00x	3.42x
EV/EBITDA	0.00x	10.26x
P/B Ratio	9.47x	422.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.12x	-41.75x
PEG Ratio	N/A	0.41x
Forward P/E (NTM)	19.86x	7.50x
Forward P/S (NTM)	N/A	3.13x
Revenue & Growth
Revenue (TTM)	$0	$1.33B
Revenue Growth (YoY)	N/A	13.6%
Forward Rev Growth	0.0%	5.4%
Profitability
Gross Margin (TTM)	0.0%	82.0%
Operating Margin (TTM)	0.0%	30.3%
EBITDA Margin (TTM)	0.0%	33.1%
Net Margin (TTM)	0.0%	26.7%
FCF Margin (TTM)	N/A	-8.2%
Net Income (TTM)	$-197M	$355M
FCF (TTM)	$-159M	$-109M
EPS (TTM)	-$1.83	$2.86
ROE (TTM)	-3901.0%	159.1%
ROA (TTM)	-3696.0%	28.1%
ROIC (TTM)	-3901.0%	29.4%
Financial Health
Cash	$72M	$222M
Debt	$0	$487M
Net Cash/Debt	$72M	$-265M
Current Ratio (TTM)	16.24x	0.84x
Quick Ratio (TTM)	16.01x	0.65x
Debt/Equity (TTM)	0.00x	27.90x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.37	0.49
52W Performance	140.1%	48.9%
YTD Performance	52.8%	-0.9%
% from 52W High	-25.2%	-17.3%
% from 52W Low	154.6%	50.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.06x
FCF Yield (TTM)	-4.1%	-2.5%
Earnings Yield (TTM)	-5.1%	8.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	5.4
EV/GP/RG	N/A	1.40
Ticker research	View EWTX research	View INDV research